12:00 AM
 | 
Sep 09, 2002
 |  BioCentury  |  Emerging Company Profile

Kiadis: The meaning in mixtures

In the target-rich post-genomics era, medicinal chemistry, target validation and toxicology remain bottlenecks in drug development. Kiadis B.V. has developed a technology for looking at complex mixtures that it says can address these key steps.

The company's technology enables decisions to be made about molecules by improving on older separation methods used to search for active compounds in complex mixtures. Indeed, the technology encourages the creation of even more complex mixtures in order to find molecules with the desired characteristics.

Traditionally, fractionation is required to separate compounds in mixtures, a process that is long and costly. In fact, according to CEO Gerard Dijkstra, "many companies abandoned natural extract screening because of the challenges when screening complex mixtures. In screening complex mixtures there can be 'matrix effects' where the activity observed was caused by several compounds working together and not just one alone." Such false positives cost time and money.

In addition to studying natural extracts,...

Read the full 756 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >